Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + RC148 vs Chemo +/- Toripalimab in HR-/HER2-low Breast Cancer
NCT06642545Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of disitamab vedotin and RC148 Injection + pemetrexed disodium for injection + carboplatin injection in breast cancer (2 arms), sponsored by RemeGen. Primary endpoint: Objective Response Rate at 24 months. Started Feb 2025; status: recruiting.
02
Drugs
disitamab vedotinRC148 Injection + pemetrexed disodium for injection + carboplatin injection
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06642545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642545.